Literature DB >> 17024231

Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.

C R J Pameijer1, A Navanjo, B Meechoovet, J R Wagner, B Aguilar, C L Wright, W-C Chang, C E Brown, M C Jensen.   

Abstract

Adoptive transfer of ex vivo expanded tumor-specific T cells is a promising therapeutic modality for promoting or augmenting antitumor immunity. Several groups, including ours, are developing antigen receptor gene transfer strategies as a means of generating effector cells for adoptive therapy. Chimeric antigen receptors (CARs) have been described that use single-chain antibodies or cytokine ligands as tumor targeting domains. Here, we describe the capacity of a tumor-binding peptide identified by phage display combinatorial library screening to serve as a CAR targeting domain. A phage library-selected high-affinity 12-mer peptide (Bpep) specific for alpha(v) beta(6) integrin (alpha v beta6) was chosen for these studies. Primary human T cells were genetically modified to express the Bpep-CAR consisting of an alpha v beta6-specific peptide and human IgG4 hinge-Fc extracellular domain fused to the cytoplasmic tail of CD3-zeta. T cell expression of the Bpep-CAR was assessed by Western blot analysis, and trafficking of the Bpep-CAR to the cell surface was demonstrated by flow cytometry. Functionally, Bpep-CAR redirected cytotoxic T lymphocytes specifically kill integrin alpha v beta6+ ovarian tumor targets, and are activated for interferon gamma secretion. Our data suggest that large new repertoires of tumor-specific T cell antigen receptor transgenes might be available through merging combinatorial peptide libraries with CAR construct design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024231     DOI: 10.1038/sj.cgt.7700993

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  22 in total

Review 1.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

Review 2.  Immunotherapy targeting EBV-expressing lymphoproliferative diseases.

Authors:  Catherine M Bollard; Laurence J Cooper; Helen E Heslop
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

Review 3.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

4.  A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv.

Authors:  E Faitschuk; V Nagy; A A Hombach; H Abken
Journal:  Gene Ther       Date:  2016-06-14       Impact factor: 5.250

Review 5.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

Review 6.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation.

Authors:  Persis P Wadia; Marc Coram; Randall J Armstrong; Michael Mindrinos; Atul J Butte; David B Miklos
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

Review 8.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 9.  Tumor-targeting peptides from combinatorial libraries.

Authors:  Ruiwu Liu; Xiaocen Li; Wenwu Xiao; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2016-05-19       Impact factor: 15.470

10.  Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.

Authors:  Lynsey M Whilding; Ana C Parente-Pereira; Tomasz Zabinski; David M Davies; Roseanna M G Petrovic; Y Vincent Kao; Shobhit A Saxena; Alex Romain; Jose A Costa-Guerra; Shelia Violette; Hiroaki Itamochi; Sadaf Ghaem-Maghami; Sabari Vallath; John F Marshall; John Maher
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.